Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Halozyme Therapeutic
(NQ:
HALO
)
55.47
-0.76 (-1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
992,574
Open
56.43
Bid (Size)
55.12 (1)
Ask (Size)
55.60 (1)
Prev. Close
56.23
Today's Range
55.24 - 56.53
52wk Range
32.83 - 57.09
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.
Via
Investor's Business Daily
Performance
YTD
+48.36%
+48.36%
1 Month
+5.94%
+5.94%
3 Month
+43.07%
+43.07%
6 Month
+61.20%
+61.20%
1 Year
+29.12%
+29.12%
More News
Read More
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
July 22, 2024
Via
Chartmill
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
July 18, 2024
Via
InvestorPlace
NASDAQ:HALO is showing good growth, while it is not too expensive.
July 18, 2024
Via
Chartmill
Biotech Arvinas Stock Earns 82 RS Rating
July 17, 2024
Via
Investor's Business Daily
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
July 16, 2024
Via
Benzinga
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
July 15, 2024
Via
Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
July 09, 2024
Via
Chartmill
Denali Therapeutics Stock Gets Technical Rating Upgrade
July 16, 2024
Via
Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
July 15, 2024
Via
InvestorPlace
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
July 12, 2024
Via
Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Via
InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
July 01, 2024
Via
InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
Via
Investor's Business Daily
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
June 24, 2024
Via
Benzinga
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
June 24, 2024
Via
Chartmill
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
June 26, 2024
Via
Chartmill
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
June 24, 2024
Via
Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
June 20, 2024
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
June 19, 2024
Via
Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Via
InvestorPlace
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Via
Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
June 12, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.